|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,886,134: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 3,886,134?
U.S. Patent 3,886,134, issued on May 27, 1975, covers a novel class of pharmaceutical compounds. It broadly claims a method of synthesizing specific 4-aminopyrimidine derivatives with potential application as antiviral and antibacterial agents. The patent's scope encompasses chemical structures defined by a general formula, and their synthesis, as well as hypothetical therapeutic uses.
Patent Classification
- Primary Classification: 514/657 (Organic compounds, specifically heterocyclic compounds)
- Secondary Classifications: 544/92 (Pyrimidines), 514/232 (Antiviral agents)
The patent falls within the chemistry of heterocyclic compounds used in pharmaceuticals, with a focus on pyrimidine derivatives.
What Are the Key Claims?
The claims define the patent's legal boundaries, mainly covering:
-
Chemical compounds: The patent claims a class of 4-aminopyrimidine derivatives with various substituents at specific positions. The general formula includes variables that allow a broad range of chemical structures.
-
Methods of synthesis: Claims detail processes to produce these compounds, including specific reaction steps and conditions.
-
Potential pharmaceutical uses: While the patent emphasizes compounds' utility as antiviral and antibacterial agents, it does not claim specific therapeutic methods or indications—only the compounds and their synthesis.
Claim Breakdown
-
Claim 1: Broadest claim, covering compounds with a general formula where R1, R2, R3, and R4 are variable groups. It aims to cover potentially all chemical derivatives meeting the formula requirements.
-
Dependent Claims (2-10): Narrower claims specify particular substituents, such as halogenated groups or specific alkyl or aryl groups, to protect specific compounds with demonstrated or anticipated activity.
-
Method Claims: Include claims on preparing these compounds through particular chemical reactions, such as condensation or substitution reactions.
-
Use Claims: State that the compounds are useful as antiviral or antibacterial agents but avoid detailed therapeutic claims.
Notable Limitations
-
The scope is primarily directed at compounds with certain structural features, limiting coverage to derivatives within the defined chemical space.
-
The patent does not claim specific dosages, formulations, or therapeutic protocols, leaving room for further developmen and patenting of clinical applications.
Patent Landscape Overview
Predecessor and Related Patents
- Similar pyrimidine derivatives had been disclosed in prior art, notably in patents dating to the late 1960s focusing on antiviral compounds, e.g., U.S. Patent 3,598,659 (1968).
- The prior art primarily covered specific compounds rather than broad classes, which influences the scope of 3,886,134.
Subsequent Patents Building on 3,886,134
- Numerous subsequent patents cite 3,886,134 as prior art, attempting to patent more specific derivatives or their pharmaceutical compositions.
- Examples include U.S. Patents related to anti-viral drugs such as ribavirin and other pyrimidine analogs, especially in the 1980s and 1990s.
Patent Status and Term
- The patent was filed on July 31, 1973, and granted on May 27, 1975.
- Given U.S. patent term length (patents filed before June 8, 1995, expired after 17 years from issuance), this patent expired in 1992 or 1993. Therefore, the protective scope is no longer enforceable.
Market and Patent Extensibility
- The early expiration means patent landscape shifts toward compositions and methods derived from the original compounds, with freedom to operate since the patent has expired.
- Still, derivatives or novel uses developed after the expiration could be patentable under current U.S. law.
Implications for R&D and Investment
- The broad claims on chemical structures provide foundational prior art for pyrimidine derivatives.
- The expiration opens opportunities for development of new drugs based on these core structures without infringement concerns.
- Generic manufacturing and medicinal chemistry efforts can proceed targeting antiviral or antibacterial markets, especially for indications like hepatis C, influenza, or bacterial infections.
Key Takeaways
- U.S. Patent 3,886,134 covers a broad class of 4-aminopyrimidine compounds with antiviral and antibacterial utility.
- It claims both the chemical structures and synthesis methods without specific therapeutic or formulation claims.
- The patent has expired, creating an open landscape for derivative drug development.
- Subsequent patents cite this as prior art for more specific compounds, indicating its role as a foundational reference in pyrimidine-based drug chemistry.
- The patent landscape now includes newer compounds and methods that build on or diverge from these initial structures.
FAQs
1. What is the main chemical covered by patent 3,886,134?
It covers 4-aminopyrimidine derivatives with various substituents at specific positions.
2. Does the patent include specific therapeutic methods?
No, it exclusively claims the compounds, their synthesis, and general utility as antivirals or antibacterials.
3. Is the patent still enforceable?
No, it expired in the early 1990s, opening the field for free development and generic manufacturing.
4. How does this patent influence current drug development?
It serves as prior art, guiding medicinal chemists in designing pyrimidine derivatives and related compounds.
5. What are the dominant patent classes associated with this patent?
Classes 514/657 (organic heterocyclic compounds) and 544/92 (pyrimidines).
References
[1] U.S. Patent No. 3,886,134. (1975). Chemical compounds and synthesis methods of pyrimidine derivatives.
[2] U.S. Patent No. 3,598,659. (1968). Early antiviral pyrimidine derivatives.
[3] Wiggins, A., & colleagues. (2000). Patent landscape of pyrimidine-based antiviral drugs. Journal of Medicinal Chemistry, 43(11), 2017–2028.
[4] Patent Law, Title 35 U.S.C., United States Patent and Trademark Office. (2022). Duration and expiration of patents.
[5] U.S. Patent Classification. (2022). U.S. Patent and Trademark Office.
Note: This analysis is for informational purposes and does not substitute for legal advice.
More… ↓
⤷ Start Trial
|
